Epitopea Secures UK Approval for Ovarian Cancer Vaccine Trial
Event summary
- Epitopea received approval from the UK MHRA and REC for a Phase 1/1b clinical trial (OVACT) of CryptiVax™-1001 in advanced high-grade serous ovarian cancer.
- Professor Susana Banerjee of The Royal Marsden has been appointed Chief Investigator for the OVACT trial.
- The trial will evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax™-1001 in HRP+/BRCA-wildtype ovarian cancer patients.
- CryptiVax™-1001 targets tumor-specific antigens identified by Epitopea’s proprietary CryptoMap™ discovery engine.
The big picture
High-grade serous ovarian cancer represents a significant unmet medical need, with limited effective maintenance therapies for HRP+/BRCA-wildtype patients. Epitopea’s approach of targeting tumor-specific antigens via an off-the-shelf mRNA vaccine represents a novel strategy, but faces the inherent risks associated with early-stage clinical development and the competitive pressures of the broader immunotherapy market. The appointment of a high-profile investigator like Professor Banerjee lends credibility to the program, but does not guarantee success.
What we're watching
- Clinical Efficacy
- The initial results of the OVACT trial will be critical in determining whether CryptiVax™-1001 demonstrates meaningful clinical activity in a patient population with limited treatment options.
- Regulatory Pathway
- Success in the Phase 1/1b trial will be necessary to establish a clear regulatory pathway for CryptiVax™-1001, particularly given the competitive landscape in ovarian cancer immunotherapy.
- Antigen Sharing
- The degree of inter-patient sharing of Cryptigens™ will ultimately dictate the breadth of potential patient populations that can benefit from Epitopea’s off-the-shelf approach, impacting commercial viability.
Our editorial coverage:
Related topics